Phase 2 study of vascular-targeted prodrug (G-202) for the treatment of recurrent glioblastoma
Ended Project Grant Awarded Last action
- Award ID
- R01FD005077
- Recipient
-
Saint John's Cancer Institute UEI RG2GTSYTHE73
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $948,855
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Funding agency
- Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
- Place of performance
- California, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$34,989 | |
| Amendment | -$34,989 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | -$77,334 | |
| Amendment | $296,167 | |
| Amendment | $400,000 | |
| Original award | $400,000 |
Quick answers
Who received award R01FD005077?
R01FD005077 was awarded to Saint John's Cancer Institute by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on April 20, 2015.
How much is award R01FD005077 worth?
$948,855 has been obligated on R01FD005077.
Which agency awarded R01FD005077?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD005077, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award